Researchers are closely watching pozelimab, a experimental antibody showing encouraging results in preliminary clinical trials . This therapeutic targets tau protein – a significant hallmark of https://gorillasocialwork.com/story27646354/pozelimab-a-new-prospect-for-this-condition